Contact
Please use this form to send email to PR contact of this press release:
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
TO:
Please use this form to send email to PR contact of this press release:
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
TO: